drugset / Trial / NCT01626573
A Study Exploring the Safety, Tolerability, and Efficacy of a 28 Day Course Followed by an Additional 56 Day Course of Itacitinib in Subjects With Active Rheumatoid Arthritis
RandomizedParallel-groupTriple-blindTreatment
Summary
This is a study evaluating a 28-day course followed by a 56-day course of itacitinib in patients with active rheumatoid arthritis (RA). The study will evaluate safety and efficacy parameters of itacitinib.
Timeline
- Start
- 2012-03
- Primary completion
- 2013-07
- Completion
- 2013-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Itacitinib | Small molecule | 100 mg | — |
| Subject | Itacitinib | Small molecule | 200 mg | — |
| Subject | Itacitinib | Small molecule | 300 mg | — |
| Subject | Itacitinib | Small molecule | 400 mg | — |
| Subject | Itacitinib | Small molecule | 600 mg | — |